Please assess the completion status of the following clinical trial:

Trial Title: CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Kidney transplant recipients under the care of the West London Renal and Transplant Centre~Exclusion Criteria:~* Patients who are unable to give written informed consent~* Simultaneous kidney/pancreas transplant recipients~* Non-heart beating deceased donor transplant recipients~* Patients who would not be offered Campath-1H induction under our current protocol (patients with previous malignancy or with previous exposure to cytotoxic or antiproliferative agents)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Campath-Tacrolimus (Type: ACTIVE_COMPARATOR): Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy
- Daclizumab-Tacrolimus-Mycophenolate (Type: EXPERIMENTAL): Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).